3.30

2.65% -0.09

Pre-market: 3.46 0.16 +4.85%

Abcellera Biologics Inc (ABCL)

Overview News Price History Option Chain Financials Why ABCL Down? Discussions Forecast

Abcellera Biologics Inc stock is traded at $3.30, with a volume of 3.92M. It is down -2.65% in the last 24 hours and down -4.35% over the past month. AbCellera Biologics Inc is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for indications with high unmet medical need. It has built a platform for advancing antibody drug programs that the company believes provides it with a competitive advantage in addressing challenging, high-value targets such as complex transmembrane proteins and novel modalities, including multispecifics and antibody-drug conjugates. Organisation's pipeline includes two drug candidates in clinical development, two development candidates in Investigational New Drug (IND/Clinical Trial Application (CTA)-enabling activities, and more than 20 active discovery programs across multiple modalities and indications. ABCL635, ABCL386, ABCL575, and ABCL635.

Previous Close:

$3.39

Open:

$3.36

24h Volume:

3.92M

Relative Volume:

1.00

Market Cap:

$1.00B

Revenue:

$75.13M

Net Income/Loss:

$-146.41M

P/E Ratio:

-6.7292

EPS:

-0.4904

Net Cash Flow:

$-174.43M

1W Performance:

-5.44%

1M Performance:

-4.35%

6M Performance:

-42.81%

1Y Performance:

+60.98%

1-Day Range:

$3.22

$3.38

1-Week Range:

$3.22

$3.67

52-Week Range:

$1.90

$6.515

Abcellera Biologics Inc Stock (ABCL) Company Profile

Name

Abcellera Biologics Inc

Sector

Healthcare (1110)

Industry

Biotechnology (624)

Phone

(604) 559-9005

Address

150 W 4TH AVENUE, VANCOUVER

Employee

562

Twitter

Next Earnings Date

2024-11-18

Latest SEC Filings

ABCL's Discussions on Twitter

Compare ABCL vs VRTX, REGN, ARGX, ALNY, INSM

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ABCL Abcellera Biologics Inc	3.30	1.00B	75.13M	-146.41M	-174.43M	-0.4904
VRTX Vertex Pharmaceuticals Inc	431.86	109.85B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	760.27	80.38B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	765.43	47.60B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	319.52	42.63B	3.71B	313.75M	465.38M	2.2571
INSM Insmed Inc	163.03	35.19B	606.42M	-1.28B	-997.58M	-6.403

Abcellera Biologics Inc Stock (ABCL) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Nov-07-25	Downgrade	Leerink Partners	Outperform → Market Perform
Jul-07-25	Resumed	Leerink Partners	Outperform
Aug-20-24	Downgrade	The Benchmark Company	Buy → Hold
Feb-22-24	Upgrade	The Benchmark Company	Hold → Buy
Dec-05-23	Initiated	KeyBanc Capital Markets	Overweight
Nov-06-23	Downgrade	The Benchmark Company	Buy → Hold
Oct-13-23	Resumed	Piper Sandler	Overweight
Feb-28-23	Initiated	Cowen	Outperform
Dec-15-22	Initiated	Goldman	Buy
Nov-16-22	Initiated	Truist	Buy
Dec-21-21	Initiated	The Benchmark Company	Buy
Nov-19-21	Initiated	Piper Sandler	Overweight
Jan-05-21	Initiated	BMO Capital Markets	Outperform
Jan-05-21	Initiated	Berenberg	Buy
Jan-05-21	Initiated	Credit Suisse	Outperform
Jan-05-21	Initiated	SVB Leerink	Outperform
Jan-05-21	Initiated	Stifel	Buy

View All

Abcellera Biologics Inc Stock (ABCL) Latest News

Apr 07, 2026

Aug Big Picture: What is AbCellera Biologics Incs P E ratio telling usTrade Ideas & Accurate Buy Signal Notifications - baoquankhu1.vn

Apr 07, 2026

Apr 06, 2026

Insider Stock Buying Reaches US$1.04m On AbCellera Biologics - Moomoo

Apr 06, 2026

AbCellera (ABCL): Among the stocks that could 10x over the next 5 years - MSN

Apr 06, 2026

Truist Financial Maintains AbCellera Biologics(ABCL.US) With Buy Rating, Announces Target Price $3.52 - Moomoo

Apr 06, 2026

Apr 05, 2026

What sparked AbCellera Biologics to soar over 9% after hours - MSN

Apr 05, 2026

Apr 03, 2026